ArticleCurrent transplantation reports2015
The Cost of Transplant Immunosuppressant Therapy: Is This Sustainable?
Article in Current transplantation reports, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 88 citations in OpenAlex.
- Hospitalization Costs of Kidney Transplantation Associated With Induction Therapy Among Pediatric Kidney Transplant Recipients: A North American Pediatric Renal Trials and Collaborative Studies and Pediatric Health Information System Collaborative Study.Pediatric transplantation · 2026Article
- Socio-Occupational Aspects in Liver Transplant Candidates and Recipients: A Retrospective Cohort Study.Journal of occupational rehabilitation · 2026Article
- Hospice Referral Rate Disparities of American Indian/Alaska Native Kidney Transplant Recipients with End-Stage Kidney Disease: A Retrospective Cohort Analysis.The American journal of hospice & palliative care · 2026Article
- Financial burden of once daily extended-release tacrolimus and twice daily immediate-release tacrolimus for kidney transplant recipients.Exploratory research in clinical and social pharmacy · 2026Article
- Predicting Hospice Use Among American Indian/Alaska Native Persons with End-Stage Kidney Disease.medRxiv : the preprint server for health sciences · 2026Article
- Cost Impact of a Novel Pre-transplant Risk Assessment Tool for Early Acute Rejection in Kidney Transplant Patients.Journal of health economics and outcomes research · 2026Article
- Annual Out-of-Pocket Medical Costs and Financial Toxicity Among Transplant Recipients in the United States.Journal of general internal medicine · 2026Article
- A two-phase digital tool to predict and prevent post-transplant hyperuricemia.Frontiers in digital health · 2026Article
- Treatment of antibody-mediated rejection in heart transplantation: from empirical combination to multi-target precision intervention.Frontiers in immunology · 2026Review
- Clustering and predicting VCA patient populations - a machine learning approach into vascularized composite allotransplantation.Frontiers in immunology · 2026Article
- Rabbit-Derived Antithymocyte Globulin-Associated Perioperative Anaphylaxis in Renal Transplantation: A Multidisciplinary Perspective on Pathophysiology, Clinical Presentation, and Management.Antibodies (Basel, Switzerland) · 2025Review
- A Pilot Study Examining Sleep Deprivation Among Liver Transplant Surgeons. Are Patient Outcomes at Risk?Clinical transplantation · 2025Article
- Beyond the pill: incrimination of nuclear factor-kappa B and their targeted phytomedicine for pulmonary fibrosis.Naunyn-Schmiedeberg's archives of pharmacology · 2025Review
- Efficacy and Safety of Mycophenolate Mofetil Compared to Azathioprine in Autoimmune Hepatitis: A Meta-Analysis.Gastroenterology research · 2025Article
- Cost-utility analysis of pharmacogenomics-guided tacrolimus treatment of Slovenian patients undergoing kidney transplantation in the U-PGx PREPARE study.The pharmacogenomics journal · 2025Article
- Personalizing immunosuppressive therapy: predictors of drug switches in Malaysian kidney transplant recipients.Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques · 2025Observational
- Long-term Prolonged-release Tacrolimus-based Immunosuppression in De Novo Kidney Transplant Recipients: 5-Y Prospective Follow-up of Patients in the ADVANCE Study.Transplantation direct · 2023Article
- Novel therapies for graft versus host disease with a focus on cell therapies.Frontiers in immunology · 2023Review
- Typical and atypical properties of peripheral nerve allografts enable novel strategies to repair segmental-loss injuries.Journal of neuroinflammation · 2022Review
- Precision Medicine in Kidney Transplantation: Just Hype or a Realistic Hope?Transplantation direct · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
A solid organ transplant is life-saving therapy that engenders the use of immunosuppressive medications for the lifetime of the transplanted organ and its recipient. Conventional therapy includes both induction therapy (a biologic that is infused peri-operatively) followed by maintenance therapy. The cost of these medications is a constant concern and the advent of generics has brought this cost down modestly. For those lacking long term insurance coverage, this may be a significant out of pocket expense that is not affordable. Moreover, transplant Centers are managing higher risk transplant recipients that require more complex induction regimens and longer term use of such biologic agents in the context of desensitization or abrogation of de novo antibody mediated injury. While in kidney transplantation, Medicare part B covers three years of medication, there is frequent non-adherence due to cost after that time-point. The impact of the Affordable Care Act remains uncertain at this time. Finally the pipeline of new therapies is limited due to the cost of development of a drug, the inherent cost of clinical studies, and lack of defined endpoints for newer therapies in high risk patients. These new therapies are of high value to the community but will contribute additional burden to current drug costs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.